Figure 2
From: CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
Referral, screening, randomization and completion of treatment. Thirty percent of 157 patients referred were randomized into the two treatment arms at baseline. Twenty-four participants were assigned to receive placebo and 23 assigned to receive 150 mg MVC b.i.d.. Seventeen participants in the placebo arm completed the study to wk 24, compared with 20 in the MVC arm. DNA, did not attend; DO, dropout; ITT, intent to treat; LTFU, lost to follow up.